摘要
Abstract
Objective To comparatively analyze the efficacy and safety of clopidogrel versus ticagrelor as antiplatelet therapy drugs for patients with acute coronary syndrome(ACS)undergoing percutaneous coronary intervention(PCI),and to evaluate the differences between the two drugs in preventing post-operative cardiovascular and bleeding events.Methods We enrolled 300 patients with ACS,and divided them into two groups based on the dual antiplatelet therapy regimen received after admission.Clopidogrel group received clopidogrel combined with aspirin(n=150),while ticagrelor group adopted ticagrelor combined with aspirin(n=150).Outpatient and telephone follow-ups were conducted to record the occurrence of major adverse cardiovascular events,bleeding events,and adverse drug reactions one month,and 3,6 and 12 months after operation.Results Compared to the clopidogrel group,the ticagrelor group demonstrated a significant advantage in reducing the risk of cardiovascular death(HR=0.09,95%CI 0.02-0.37,P<0.01),and also showed a notable effect in reducing all-cause mortality(HR=0.12,95%CI 0.05-0.34,P<0.05).However,there were no statistically significant differences between the two groups in the incidences of stroke,recurrent myocardial infarction,or severe bleeding events(all P>0.05).Conclusion Ticagrelor shows superior efficacy compared to clopidogrel in preventing major adverse cardiovascular events in ACS patients after PCI,particularly in significantly reducing the risk of cardiovascular death.关键词
急性冠脉综合征/氯吡格雷/替格瑞洛/抗血小板治疗Key words
acute coronary syndrome/clopidogrel/ticagrelor/antiplatelet therapy分类
医药卫生
